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IMPORTANCE The clinical management of BRCA1 and BRCA2mutation carriers requires
accurate, prospective cancer risk estimates.
OBJECTIVES Toestimate age-specific risks of breast, ovarian, and contralateral breast cancer for
mutation carriers and toevaluate riskmodificationby family cancer history andmutation location.
DESIGN, SETTING, AND PARTICIPANTS Prospective cohort study of 6036 BRCA1 and 3820
BRCA2 female carriers (5046 unaffected and 4810with breast or ovarian cancer or both
at baseline) recruited in 1997-2011 through the International BRCA1/2 Carrier Cohort Study,
the Breast Cancer Family Registry and the Kathleen Cuningham Foundation Consortium for
Research into Familial Breast Cancer, with ascertainment through family clinics (94%) and
population-based studies (6%). Themajority were from large national studies in the United
Kingdom (EMBRACE), the Netherlands (HEBON), and France (GENEPSO). Follow-up ended
December 2013; median follow-up was 5 years.
EXPOSURES BRCA1/2mutations, family cancer history, andmutation location.
MAIN OUTCOMES ANDMEASURES Annual incidences, standardized incidence ratios, and
cumulative risks of breast, ovarian, and contralateral breast cancer.
RESULTS Among 3886women (median age, 38 years; interquartile range [IQR], 30-46 years)
eligible for the breast cancer analysis, 5066women (median age, 38 years; IQR, 31-47 years)
eligible for the ovarian cancer analysis, and 2213 women (median age, 47 years; IQR, 40-55
years) eligible for the contralateral breast cancer analysis, 426 were diagnosed with breast
cancer, 109 with ovarian cancer, and 245 with contralateral breast cancer during follow-up.
The cumulative breast cancer risk to age 80 years was 72% (95% CI, 65%-79%) for BRCA1
and 69% (95% CI, 61%-77%) for BRCA2 carriers. Breast cancer incidences increased rapidly in
early adulthood until ages 30 to 40 years for BRCA1 and until ages 40 to 50 years for BRCA2
carriers, then remained at a similar, constant incidence (20-30 per 1000 person-years) until
age 80 years. The cumulative ovarian cancer risk to age 80 years was 44% (95% CI,
36%-53%) for BRCA1 and 17% (95% CI, 11%-25%) for BRCA2 carriers. For contralateral breast
cancer, the cumulative risk 20 years after breast cancer diagnosis was 40% (95% CI,
35%-45%) for BRCA1 and 26% (95% CI, 20%-33%) for BRCA2 carriers (hazard ratio [HR] for
comparing BRCA2 vs BRCA1,0.62; 95% CI, 0.47-0.82; P=.001 for difference). Breast cancer
risk increased with increasing number of first- and second-degree relatives diagnosed as
having breast cancer for both BRCA1 (HR for2 vs 0 affected relatives, 1.99; 95% CI,
1.41-2.82; P<.001 for trend) and BRCA2 carriers (HR, 1.91; 95% CI, 1.08-3.37; P=.02 for trend).
Breast cancer risk was higher if mutations were located outside vs within the regions
bounded by positions c.2282-c.4071 in BRCA1 (HR, 1.46; 95% CI, 1.11-1.93; P=.007) and
c.2831-c.6401 in BRCA2 (HR, 1.93; 95% CI, 1.36-2.74; P<.001).
CONCLUSIONS AND RELEVANCE These findings provide estimates of cancer risk based on
BRCA1 and BRCA2mutation carrier status using prospective data collection and demonstrate
the potential importance of family history andmutation location in risk assessment.
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T heoptimal clinicalmanagement ofwomenwithBRCA1and BRCA2 mutations depends on accurate age-specific cancer risk estimates. These can be used to es-
timate the absolute risk reduction from preventive strategies
and to inform decisions about the age at which to commence
cancer screening.1
Basedon retrospective studies,2-11 cumulative breast can-
cer risk estimates to age 70 years range from 40% to 87% for
BRCA1 and from 27% to 84% for BRCA2 carriers. The corre-
spondingovariancancer risksvary from16%to68%forBRCA1
and from 11% to 30% for BRCA2 carriers. Risk estimates from
these studies had wide confidence intervals. Differences in
sampling(population-based/high-risk families),populationand
mutation characteristics, analytic methods, and other ge-
netic and lifestyle/hormonal factors are possible explana-
tions for the variation in risk estimates.12
BecauseBRCA1andBRCA2mutationsare rare in thepopu-
lation,most retrospectivepenetranceestimateshavebeende-
rived from family-based studies. Typically, mutation screen-
ing has been performed among affected women, selected on
the basis of young age at diagnosis or cancer family history.
Cancer risks are then estimated using the known or inferred
genotypes of the relatives. Estimates from such retrospec-
tive, family-based studies are prone to bias if analyses are not
correctly adjusted for the ascertainmentprocess or if there are
inaccuracies in family history.
Prospective cohort studies, inwhichmutation carriers are
recruited on the basis of their mutation status and followed
over time,mayavoid these issues.Because theprecisionof risk
estimatesdependson thenumberofprospective incident can-
cers, a very large samplewith long follow-up is required. Pro-
spective penetrance estimates have been based on small
samples (<64 breast cancers, 31 ovarian cancers) and are
imprecise.13-15 The purpose of this studywas to estimate age-
specific risks of breast, ovarian, and contralateral breast can-
cer using data from a large prospective cohort.
Methods
Participants
We used prospective cohort data on carriers of pathogenic
BRCA1 and BRCA2 mutations recruited through 3 consortia,
the International BRCA1/2 Carrier Cohort Study (IBCCS), the
Breast Cancer Family Registry (BCFR), and the Kathleen Cun-
ingham Foundation Consortium for Research Into Familial
Breast Cancer (kConFab) (eAppendix in the Supplement). All
centers in these consortia obtained written informed consent
from study participants and local ethical review committees
approved protocols.
Briefly, for the IBCCS, data were available from 7666
female carriers recruited between 1997 and 2011 from
18 European cancer genetics centers and the Quebec prov-
ince of Canada. The majority were from large national
studies in the United Kingdom, the Netherlands, and France.
All centers conducted active follow-up through question-
naires. In addition to the active follow-up in all studies, pas-
sive follow-up through linkage with cancer, pathology, and
death registries was obtained in countries where this is avail-
able (cancer/death registries in Denmark, the Netherlands,
Sweden, and the United Kingdom; pathology registries to col-
lect information on preventive surgeries in Denmark and the
Netherlands), together with medical record validation of self-
reported cancer diagnoses and preventive surgeries.
The BCFR is a family cohort that includes data on 1570
mutation carriers recruited from 6 sites in Australia, Canada,
and the United States. Families were followed up regularly
through annual approaches to probands and 5-year system-
atic follow-upof families collectingepidemiological anddemo-
graphic data from all participants.
The kConFab study included 620 mutation carriers
frommultiple-case families ascertained through family can-
cer clinics in Australia and New Zealand since 1997. Partici-
pants were systematically followed up using a questionnaire
mailed every 3 years.
The end of follow-up was December 2013.
Eligibility and Censoring
For each of the 3 analyses (breast cancer risk, contralateral
breast cancer risk, and ovarian cancer risk), we defined a dif-
ferent groupeligible at baseline (Figure 1). Age at baselinewas
defined as age at study recruitment or age at the genetic test,
whichever was more recent.
Breast Cancer Risk
Women were included in the estimation of first breast can-
cer risk if at completion of the baseline questionnaire they
had not been diagnosed as having any cancer (excluding
nonmelanoma skin cancer) nor undergone risk-reducing
bilateral mastectomy (with mastectomy: n = 304 BRCA1;
n = 148 BRCA2) (eAppendix in the Supplement). Women
were followed up from baseline until the first of the follow-
ing: age 80 years; death; completion of last follow-up ques-
tionnaire or last record linkage (if conducted), whichever
happened last; risk-reducing bilateral mastectomy; or diag-
nosis of any first cancer (excluding nonmelanoma skin can-
cer). Women diagnosed as having breast cancer (invasive or
noninvasive [ductal carcinoma in situ]) during follow-up
were considered as affected. Because information on can-
cers was partly self reported, tumor phenotype–specific
Key Points
Question What are the breast and ovarian cancer risks for BRCA1
and BRCA2mutation carriers and are they related to family history
of cancer andmutation position?
Findings From a prospective cohort of 9856mutation carriers,
mainly ascertained through cancer genetic clinics, the cumulative
breast cancer risk to age 80 years was 72% for BRCA1 and 69% for
BRCA2 carriers. The cumulative ovarian cancer risk to age 80 years
was 44% for BRCA1 and 17% for BRCA2 carriers. Cancer risks
differed by cancer family history andmutation position.
Meaning These findings provide cancer risk patterns based on
BRCA status using prospective data. Family history andmutation
position are important additional variables in risk assessment.
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data were not available other than for invasiveness. There-
fore, all types of breast cancer were included in the analysis.
Additional analyses were performed in which (1) affected
women were considered to be only those diagnosed as hav-
ing invasive disease and (2) women were censored at the
age of risk-reducing salpingo-oophorectomy (eAppendix).
Ovarian Cancer Risk
Women were included in the ovarian cancer analysis if at
baseline they had not been diagnosed as having ovarian can-
cer nor undergone risk-reducing salpingo-oophorectomy
(with oophorectomy: n = 1808 BRCA1; n = 969 BRCA2).
Women with a history of breast or nonmelanoma skin cancer
were included in the analysis but women with other cancers
were not. Women were followed up from baseline until the
first of the following: age 80 years; death; completion of last
follow-up questionnaire or last record linkage (whichever
happened last); risk-reducing salpingo-oophorectomy (or sal-
pingectomy or removal of ovaries for other reasons); or any
cancer diagnosis (excluding breast and nonmelanoma skin
cancer). Only women diagnosed as having invasive ovarian
(or fallopian tube or peritoneal) cancer during follow-up were
considered affected.
Contralateral Breast Cancer Risk
Women were included in the contralateral breast cancer
analysis if they were diagnosed as having a first breast cancer
before the date of their last follow-up questionnaire (or rec-
ord linkage) and had not been diagnosed as having any other
cancer (including contralateral breast cancer) nor undergone
risk-reducing bilateral mastectomy before study entry. Only
asynchronous contralateral breast cancer was considered, for
which there had to be an interval of at least 1 year between
first and second breast cancers. Eligible women entered
follow-up at their baseline questionnaire date or 1 year after
their first breast cancer diagnosis date (whichever was later)
and were followed up until the first of the following: age 80
years; death; date at last follow-up; risk-reducing bilateral
mastectomy; or any cancer. Women diagnosed as having
asynchronous contralateral breast cancer during follow-up
were assumed to be affected.
Statistical Analysis
Annual incidences of breast, ovarian, and contralateral breast
cancer per 1000 person-years were estimated for 10-year age
intervals using standard cohort analysis. Kaplan-Meier analy-
sis was used to estimate cumulative risks. Standardized inci-
dence ratios (SIRs) for breast and ovarian cancer relative to
population-specific incidenceswere also estimated (eAppen-
dix in the Supplement).
We used Cox-regression to compare cancer risks for
BRCA1 mutation carriers with risks for BRCA2 carriers
across all age groups and by attained age. To test for hetero-
geneity by country, we carried out Cox regression estimat-
ing hazard ratios (HRs) for each country (n=6) compared
with the baseline (United Kingdom); a χ2 (n − 1) degree-of-
freedom test was carried out on the estimated HRs to test
for heterogeneity. The contralateral breast cancer analysis
was stratified by age at first breast cancer (<40 years, 40-49
years, or ≥50 years) and Cox regression was used to compare
risks between age groups. We evaluated cancer risks by
extent of self-reported family history of breast or ovarian
cancer separately (eAppendix in the Supplement). Women
were classified by the number of cancers in first- or second-
degree relatives (0, 1, or ≥2). Separate categories for women
with cancers of unknown type among relatives and for
those with unknown family history (missing data) were
defined, and separate HRs were estimated for these catego-
ries. A test for trend was performed using Cox regression by
including a continuous variable in the model representing
the number of breast or ovarian cancers in female first- or
second-degree relatives (taking values of 0, 1, 2, 3, etc).
Figure 1. Assembly of Analysis Cohorts
3886 Included in analysis of breast cancer risk
2276 BRCA1 mutation carriers
1610 BRCA2 mutation carriers
5066 Included in analysis of ovarian cancer risk
 2905 BRCA1 mutation carriers
 2161 BRCA2 mutation carriers
2213 Included in analysis of contralateral
breast cancer risk
1305 BRCA1 mutation carriers
908 BRCA2 mutation carriers
9856 BRCA1 or BRCA2 mutation carriers
7643 Excluded from analysis of contralateral
breast cancer risk
867 Previous contralateral breast cancer
diagnosis
306 Previous ovarian cancer diagnosis
254 Previous other cancer diagnosis
828 Risk-reducing bilateral mastectomy
256 No follow-up
5132 No first breast cancer diagnosis by
end of follow-up
4790 Excluded from analysis of ovarian cancer risk
851 Previous ovarian cancer diagnosis
427 Previous other cancer diagnosis
2777 Risk-reducing salpingo-oophorectomya
735 No follow-up
5970 Excluded from analysis of breast cancer risk
4116 Previous first breast cancer diagnosis
452 Risk-reducing bilateral mastectomya
550 No follow-up
562 Previous ovarian cancer diagnosis
290 Previous other cancer diagnosis
a After exclusion of women in the preceding categories.
Research Original Investigation Risks of Breast, Ovarian, and Contralateral Breast Cancer Among BRCAMutation Carriers
2404 JAMA June 20, 2017 Volume 317, Number 23 (Reprinted) jama.com
© 2017 American Medical Association. All rights reserved.
Downloaded From: http://jamanetwork.com/ by a Institute of Cancer Research UK User  on 08/01/2017
Separate variables were derived for the number of breast
cancers and number of ovarian cancers in relatives. We also
evaluated differences in breast and ovarian cancer by muta-
tion position (based on base-pair location) using Cox regres-
sion. Mutations were grouped into regions based on differ-
ences in breast and ovarian cancer risks previously reported
in retrospective studies.16-18 Mutations in BRCA1 were
grouped into 3 regions (5′ to c.2281, c.2282 to c.4071, c.4072
to 3′). For BRCA2, mutations were grouped in 3 regions
using both the narrow and broad definitions of the ovarian
cancer cluster region16 (OCCR; broad definition: 5′ to c.2830,
c.2831 to c.6401, c.6402 to 3′; narrow definition: 5′ to
c.3846, c.3847 to c.6275, c.6276 to 3′; see eAppendix). For
all analyses, a robust variance approach that clustered
observations on family membership was used to adjust
standard errors for the fact that the cohort included mul-
tiple women from the same family.19 Analyses were strati-
fied by country (United Kingdom, France, the Netherlands,
Australia, United States, or other) and birth cohort (before
1940, 1940-1949, 1950-1959, 1960-1969, 1970-1979, or 1980
or later). Proportionality was evaluated using Schoenfeld
residuals, which was met for all analyses. Analyses were
carried out in Stata version 13 (Stata Corp). Statistical tests
were considered significant based on 2-sided hypothesis
tests with P < .05.
Results
A total of 9856 participants including 6036 BRCA1 and 3820
BRCA2mutation carriers were available at baseline. The ma-
jorityofwomenwereascertained through familyclinics (94%),
and the remainder (6%)were recruited fromstudies that used
population-based ascertainment. Figure 1 and eTable 1 in the
Supplement summarize the baseline cohort study sample
(N = 9856) and the assembly of the eligible prospective co-
horts for each analysis. Table 1 summarizes the characteris-
tics of the eligible women included in the prospective analy-
ses. Informationon follow-up completeness is summarized in
eTable 2 in the Supplement. All studies conducted active fol-
low-up with questionnaires, but the mean interval between
questionnaires varied across studies (1.6 to 8.7 years) (eTable
2). In addition, in countries with registry information, active
follow-upwas complementedwithpassive follow-up through
record linkage. On average, 7% of women in the cohort were
lost to follow-up, but this varied among studies (0% to 13%)
(eTable 2).
The breast cancer analysis was based on 3886 eligible
BRCA1 and BRCA2 mutation carriers (median age at study
entry, 38 years; interquartile range [IQR], 30-46 years). The
ovarian cancer analysis was based on data from 5066 women
(median age at study entry, 38 years; IQR, 31-47 years) and
the contralateral breast cancer analysis was based on 2213
women (median age at start of follow-up, 47 years; IQR,
40-55 years). During follow-up, among the eligible women,
426 were diagnosed as having breast cancer (483 censored
for risk-reducing bilateral mastectomy), 109 were diagnosed
as having ovarian cancer (1508 censored for risk-reducing
salpingo-oophorectomy), and 245 were diagnosed as having
asynchronous contralateral breast cancer. The age-specific
cancer incidences, SIRs, and cumulative risks are shown in
Table 2.
Breast Cancer Risks
For BRCA1 carriers, the breast cancer incidences per decade
of age increased from 21 to 30 years to 31 to 40 years but then
remained at 23.5 to 28.3 per 1000 person-years for ages 31 to
70years (P = .97 for trend). Thepeak incidenceoccurred in the
41- to 50-year agegroup (28.3 [95%CI, 23.1-34.7] per 1000per-
son-years).A similar patternwas seen forBRCA2 carriers,with
peak incidence in the 51- to 60-year age group (30.6 [95% CI,
22.8-41.1]per 1000person-years) and incidencesof21.9 to30.6
per 1000 person-years across ages 41 to 80 years (P = .57 for
trend). The estimated SIRs decreased with increasing age in
both BRCA1 carriers (P<.001 for trend) and BRCA2 carriers
(P<.001 for trend). The cumulative risk of breast cancer by age
80 years was 72% (95% CI, 65%-79%) for BRCA1 carriers and
69% (95% CI, 61%-77%) for BRCA2 carriers (Figure 2). While
the cumulative risks for BRCA1 and BRCA2 carriers to age 80
years were similar, the cumulative risks to age 50 years were
higher for BRCA1 carriers (P = .03).
The cumulative risk estimates for breast cancer by age 80
years when censoring at risk-reducing salpingo-oophorec-
tomywere70%(95%CI,60%-80%) forBRCA1carriersand75%
(95%CI, 67%-83%) forBRCA2 carriers (eTable 3 and eFigure 1
in the Supplement). Fromananalysis that excludedknown in
situbreast cancers, thecorresponding riskestimateswere68%
(95%CI, 60%-76%) forBRCA1 carriers and63% (95%CI, 54%-
72%) for BRCA2 carriers (eTable 4 in the Supplement).
There were no significant differences in the estimated
breast cancer incidences by country for either BRCA1 carriers
(P = .32 forheterogeneity)orBRCA2carriers (P = .43 forhetero-
geneity) (eTable 5 and eFigure 2 in the Supplement). The es-
timated breast cancer risks were similar when analyses were
carried out separately for women identified through family
clinics and women who were relatives of mutation carriers
identified through populationwide screening of breast can-
cer cases (eTable 6 in the Supplement).
Ovarian Cancer Risks
Therewas an increase inovarian cancer incidencewith ageup
to 61 to 70 years for both BRCA1 and BRCA2 carriers. The in-
cidenceswerehigher forBRCA1 carriers (HRcomparingBRCA1
vsBRCA2, 3.6; 95%CI, 2.2-5.9;P < .001). TheSIRsdidnotvary
withage foreithergene (BRCA1: overall SIR,49.6 [95%CI,40.0-
61.5];P = .86 for trend;BRCA2: 13.7 [95%CI, 9.1-20.7];P = .23
for trend). The ovarian cancer cumulative risk to age 80 years
was 44% (95%CI, 36%-53%) forBRCA1 carriers and 17% (95%
CI, 11%-25%) for BRCA2 carriers (Table 2 and Figure 2).
Contralateral Breast Cancer Risks
The estimated incidence of contralateral breast cancer for
BRCA1 carriers varied between 23 and 28 per 1000 person-
years for the period up to 20 years after the first breast cancer
diagnosis (Table 3; eTable 7 in the Supplement). The cumula-
tive risk of contralateral breast cancer 20 years after the first
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breast cancer diagnosis was 40% (95% CI, 35%-45%). The HR
for contralateral breast cancer declined with increasing age at
the first breast cancer diagnosis (for women with first breast
cancer at age 40-50 years, HR, 0.81 [95% CI, 0.58-1.12], and
for womenwith first breast cancer at age >50 years, 0.71 [95%
CI, 0.45-1.11], relative to women with first breast cancer at
age <40 years).
ForBRCA2 carriers, theestimatedcontralateral breast can-
cer incidence varied between 13 and 18 per 1000 person-
years during the years after the first breast cancer diagnosis.
The cumulative risk of contralateral breast cancer at 20 years
after the first breast cancer diagnosis was 26% (95%CI, 20%-
33%) and was lower than for BRCA1 carriers (HR comparing
BRCA2 vs BRCA1 carriers, 0.62; 95% CI, 0.47-0.82; P = .001).
Table 1. Numbers ofMutation Carriers and Incident Cancers Per Study Group Eligible for Each of the Analyses
andOther Summary Statistics
Analysis and Study All Carriers BRCA1 BRCA2
Breast Cancer Analysisa
Eligible, No.b
IBCCS 2691 1624 1067
BCFR 582 327 255
kConFab 613 325 288
All 3886 2276 1610
Incident breast cancers, No.
IBCCS 250 164 86
BCFR 83 50 33
kConFab 93 55 38
All 426 269 157
Invasive breast cancers 366 240 126
Ductal carcinoma in situ 60 29 31
Age at start of follow-up, median (IQR), y 38 (30-46) 37 (29-45) 39 (31-48)
Follow-up time, median (IQR), yc 5 (2-7) 5 (2-8) 4 (2-7)
Age at cancer diagnosis, median (IQR), y 45 (38-53) 44 (37-51) 48 (42-56)
Ovarian Cancer Analysisd
Eligible, No.b
IBCCS 3493 2059 1434
BCFR 1022 558 464
kConFab 551 288 263
All 5066 2905 2161
Incident ovarian cancers, No.
IBCCS 67 51 16
BCFR 26 23 3
kConFab 16 11 5
All 109 85 24
Age at start of follow-up, median (IQR), y 38 (31-47) 37 (30-45) 40 (33-50)
Follow-up time, median (IQR), yc 4 (2-7) 4 (2-7) 4 (2-7)
Age at cancer diagnosis, median (IQR), y 54.5 (46-63) 54 (43.5-62.5) 59.5 (53.3-64.7)
Contralateral Breast Cancer Analysise
Eligible, No.b
IBCCS 1576 949 627
BCFR 562 310 252
kConFab 75 46 29
All 2213 1305 908
Incident contralateral cancers, No.
IBCCS 152 110 42
BCFR 87 58 29
kConFab 6 5 1
All 245 173 72
Age at start of follow-up, median (IQR), y 47 (40-55) 46 (38-53) 49 (42-57)
Follow-up time, median (IQR), yc 4 (2-7) 5 (2-7) 4 (2-7)
Age at cancer diagnosis, median (IQR), y 51 (42-57.5) 48 (41-57) 51 (44-59)
Abbreviations: BCFR, Breast Cancer
Family Registry; IBCCS, International
BRCA1/2 Carrier Cohort Study;
IQR, interquartile range; kConFab,
Kathleen Cuningham Foundation
Consortium for Research Into Familial
Breast Cancer.
a Women free of all cancers and who
did not have risk-reducing bilateral
mastectomy at baseline.
b Eligibility for each analysis is
described in the “eligibility and
censoring” methods section.
c After taking into account the
censoring process.
dWomen free of ovarian or other
(nonbreast) cancer and who did not
have risk-reducing
salpingo-oophorectomy at baseline.
eWomen diagnosed as having
unilateral breast cancer and who
were free of other cancers and who
did not have risk-reducing bilateral
mastectomy at start of follow-up.
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The HR for contralateral breast cancer when first breast can-
cerdiagnosiswasbetweenages40and50yearswas0.73 (95%
CI, 0.41-1.26), andwhen the first breast cancer diagnosis was
at age greater than 50 years, the HR was 0.76 (95% CI, 0.43-
1.36) comparedwith a first breast cancer before age 40 years.
When women were censored at the age of risk-reducing
salpingo-oophorectomy, the contralateral breast cancer risks
at 20years after the first breast cancerwere 38% (95%CI, 31%-
45%) forBRCA1 carriers and34%(95%CI, 25%-45%) forBRCA2
carriers (eTable 8 in the Supplement).
To investigate potential survival bias, the analysis was
repeated after excluding women whose first breast cancer
diagnosis occurred more than 5 years prior to study recruit-
ment. The estimated cumulative risk of contralateral breast
Table 2. Breast and Ovarian Cancer Incidence Rates Per 1000 Person-Years, Kaplan-Meier Estimates of the Cumulative Risks, and Standardized
Incidence Rates by 10-Year Age Groups
Age, During Follow-up, ya
No. of Women
Contributing
in Age Categorya
No. of
Person-Years
No. of
Events
Incidence per
1000 Person-Years
(95% CI)
Cumulative Risk,
% (95% CI)b
Standardized
Incidence Rate
(95% CI)c
Breast Cancer
BRCA1 mutation carriers
≤20 53 74.0 0 0
21-30 605 2222.5 13 5.9 (3.4-10.1) 4 (2-7) 73.7 (42.9-126.8)
31-40 1048 3831.6 90 23.5 (19.1-28.9) 24 (21-29) 46.2 (37.3-57.1)
41-50 870 3317.8 94 28.3 (23.1-34.7) 43 (39-48) 17.2 (14.0-21.2)
51-60 479 1905.9 49 25.7 (19.4-34.0) 56 (51-61) 9.7 (7.2-12.9)
61-70 201 761.3 19 25.0 (15.9-39.1) 66 (61-72) 7.0 (4.5-11.0)
71-80 55 243.0 4 16.5 (6.2-43.9) 72 (65-79) 4.8 (1.8-12.8)
Total 2276d 12356.1 269 21.8 (19.3-24.5) 16.6 (14.7-18.7)
BRCA2 mutation carriers
≤20 30 44.0 0 0
21-30 329 1046.0 5 4.8 (2.0-11.5) 4 (2-9) 60.8 (25.5-144.9)
31-40 625 2136.1 23 10.8 (7.2-16.2) 13 (9-19) 20.3 (13.5-30.5)
41-50 669 2365.0 65 27.5 (21.6-35.1) 35 (29-41) 16.4 (12.9-20.9)
51-60 384 1437.2 44 30.6 (22.8-41.1) 53 (46-59) 11.4 (8.4-15.5)
61-70 174 610.2 14 22.9 (13.6-38.7) 61 (55-68) 6.4 (3.8-10.7)
71-80 68 274.6 6 21.9 (9.8-48.6) 69 (61-77) 6.6 (3.0-14.7)
Total 1610d 7913.1 157 19.8 (17.0-23.2) 12.9 (11.1-15.1)
Ovarian Cancer
BRCA1 mutation carriers
≤20 53 74.0 0 0
21-30 667 2493.0 0 0
31-40 1464 5506.6 10 1.8 (1.0-3.4) 2 (1-3) 41.4 (22.27-76.8)
41-50 1061 3558.2 25 7.0 (4.7-10.4) 8 (6-12) 56.7 (38.05-84.5)
51-60 501 1744.7 24 13.8 (9.2-20.5) 20 (16-26) 53.3 (35.78-79.5)
61-70 230 817.3 24 29.4 (19.7-43.8) 41 (33-50) 69.1 (45.17-105.7)
71-80 88 351.0 2 5.7 (1.4-22.8) 44 (36-53) 11.8 (2.94-47.0)
Total 2905d 14544.8 85 5.8 (4.7-7.2) 49.6 (40.0-61.5)
BRCA2 mutation carriers
≤20 30 44.0 0 0
21-30 353 1134.0 0 0
31-40 831 2953.0 1 0.3 (0.1-2.4) 0 (0-2) 7.3 (1.03-51.9)
41-50 862 2961.0 0 0 0 (0-2)e
51-60 534 1836.5 12 6.5 (3.7-11.5) 7 (4-11) 24.5 (13.91-43.1)
61-70 267 974.0 10 10.3 (5.5-19.1) 15 (10-23) 21.5 (11.20-41.3)
71-80 108 435.0 1 2.3 (0.3-16.3) 17 (11-25) 4.4 (0.62-31.0)
Total 2161d 10337.5 24 2.3 (1.6-3.5) 13.7 (9.1-20.7)
a Each woman could contribute to more than 1 age category.
bKaplan-Meier estimate.
c Standardized incidence rates for breast cancer and ovarian cancer
relative to population-specific incidences. Age- and calendar period–specific
population disease incidences were obtained from Cancer in Five Continents
(http://ci5.iarc.fr/Default.aspx) and NORDCAN (http://www-dep.iarc.fr
/NORDCAN/english/frame.asp).
d Total number of women contributing to the overall analysis.
e Remains equal to the estimate in the previous age group because there
are no events.
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cancer at 20 years after the first breast cancer diagnosis was
41% (95% CI, 32%-53%) for BRCA1 and 21% (95% CI, 15%-
50%) for BRCA2 carriers.
Breast and Ovarian Cancer Risks by Family History
The estimated cumulative breast and ovarian cancer risks by
familyhistoryare showninTable4andeFigure3 in theSupple-
ment. Breast cancer risk estimates for bothBRCA1 andBRCA2
carriers increased with the number of first- and second-
degree relativesdiagnosedashavingbreast cancer (P<.001 for
trend forBRCA1;P=.02 forBRCA2) (Table 4). Forwomenwith
2 or more first- or second-degree relatives diagnosed as hav-
ing breast cancer comparedwith thosewith no family history
ofbreast cancer, theHRforbreast cancerwas 1.99 (95%CI, 1.41-
2.82) for BRCA1 carriers (cumulative risk estimates to age 70
years: 73%[95%CI,65%-80%]vs53%[95%CI, 39%-69%]) and
theHR forbreast cancerwas 1.91 (95%CI, 1.08-3.37) forBRCA2
carriers (cumulative risks to age 70 years: 65% [95% CI, 56%-
74%] vs 39% [95% CI, 25%-56%]) (Table 4).
There was no significant difference in ovarian cancer
risk for BRCA1 carriers with family history of ovarian cancer
compared with those without (HR, 1.37; 95% CI, 0.89-2.11)
(Table 4; eFigure 3 in the Supplement). A similar pattern
was observed for BRCA2 carriers, but the number of events
for women with ovarian cancer family history was small
(n = 5). Results were similar when family history of cancer
was restricted to first-degree relatives (eTable 9 in the
Supplement) or when analyses were stratified by the pres-
ence of family history of breast or ovarian cancer (eTables
10-13 in the Supplement). For BRCA1 mutation carriers, the
risk of breast cancer was lower for women with a family his-
tory of ovarian cancer compared with those with no family
history of ovarian cancer (HR, 0.71 [95% CI, 0.51-0.99] in
women with a family history of breast cancer; HR, 0.38
[95% CI, 0.21-0.70] in those without) (eTable 12).
Breast and Ovarian Cancer Risks byMutation Position
BRCA1 mutations located outside the region bounded by
positions c.2282 to c.4071 were associated with a signifi-
cantly higher breast cancer risk compared with mutations
within the region (HR, 1.46; 95% CI, 1.11-1.93; P = .007)
(Table 5; eFigure 4 in the Supplement), but there was no sig-
nificant difference in ovarian cancer risk. There was no
significant difference in the breast or ovarian cancer risks for
either the BRCA1 c.68_69delAG or c.5266dupC mutations
compared with BRCA1 mutations in the same region
(Table 5). BRCA2 mutations outside the OCCR were associ-
ated with a significantly higher breast cancer risk compared
with mutations within the OCCR (based on the narrow
OCCR definition: HR, 1.70 [95% CI, 1.18-2.46]; P = .005; based
on the broad OCCR definition: HR, 1.93 [95% CI, 1.36-2.74];
P < .001) (Table 5), but there was no significant difference in
ovarian cancer risk. There was no significant difference
in breast cancer risk for BRCA2 c.5946delT mutation carriers
compared with other OCCR BRCA2 mutations (HR, 0.73;
95% CI, 0.35-1.54; P = .41). The associations by mutation
position remained significant after adjusting for family
history of breast cancer and after excluding carriers of the
BRCA2 c.5946delT mutation from the OCCR (eTable 14 in
the Supplement).
Discussion
This study estimated age-specific risks of breast, ovarian, and
contralateral breast cancer for BRCA1 and BRCA2 mutation
Figure 2. Estimated Cumulative Risks of Breast and Ovarian Cancer inMutation Carriers
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Kaplan-Meier estimates of cumulative risks of breast and ovarian cancers.
In the breast cancer analysis, womenwere censored at risk-reducing bilateral
mastectomy. In the ovarian cancer analysis, womenwere censored for
risk-reducing salpingo-oophorectomy. Number at risk indicates the number
of womenwho remained at risk at the end of the 10-year age category
(eg, in panel A, there were 138 womenwith BRCA1mutations still at risk of
breast cancer at the end of the age 50-60 years period). The earliest follow-up
started at age 18 years.
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Table 3. Contralateral Breast Cancer Incidence Rates Per 1000 Person-Years and Kaplan-Meier Estimates of the Cumulative Risks of Contralateral
Breast Cancer by Time Since First Breast Cancer, Overall and Stratified by Age at First Breast Cancer
Years Since First Breast Cancer Diagnosis
No. of Women
Contributing
in Category
No. of
Person-Years
No. of
Events
Incidence Rate per
1000 Person-Years
(95% CI)
Cumulative Risk, %
(95% CI)
BRCA1
≤5 827 2107 60 28.5 (22.1-36.7) 13 (10-16)
>5-10 618 2071 53 25.6 (19.6-33.5) 23 (20-27)
>10-15 435 1438 33 22.9 (16.3-32.3) 32 (28-36)
>15-20 236 675 17 25.2 (15.7-40.5) 40 (35-45)
>20-45 132 661 10 15.1 (8.1-28.1) 53 (44-62)
First breast cancer diagnosis at age <40 y
≤5 370 920 31 33.7 (23.7-47.9) 15 (11-21)
>5-10 278 945 28 29.6 (20.5-42.9) 27 (21-33)
>10-15 217 739 20 27.1 (17.5-41.9) 36 (30-43)
>15-20 129 378 8 21.2 (10.6-42.3) 43 (36-50)
>20-45 70 343 6 17.5 (7.9-38.9) 60 (46-74)
First breast cancer diagnosis at age ≥40-50 y
≤5 283 725 15 20.7 (12.5-34.3) 10 (6-16)
>5-10 225 718 19 26.5 (16.9-41.5) 21 (15-28)
>10-15 152 480 11 22.9 (12.7-41.4) 30 (23-38)
>15-20 74 222 6 27.0 (12.1-60.2) 39 (30-49)
>20-39 52 280 4 14.3 (5.4-38.1 49 (37-62)
First breast cancer diagnosis at age ≥50 y
≤5 174 462 14 30.3 (17.9-51.2) 14 (8-22)
>5-10 115 408 6 14.7 (6.6-32.7) 20 (14-30)
>10-15 66 219 2 9.1 (2.3-36.5) 24 (16-35)
>15-20 33 75 3 40.0 (12.9-124.0) 38 (24-57)
>20-27 10 38 0 0.0 38 (24-57)
BRCA2
≤5 565 1468 27 18.4 (12.6-26.8) 8 (6-12)
>5-10 476 1543 26 16.9 (11.5-24.8) 16 (12-21)
>10-15 285 880 11 12.5 (6.9-22.6) 21 (17-26)
>15-20 138 355 5 14.1 (5.9-33.8) 26 (20-33)
>20-43 68 290 3 10.3 (3.3-32.1) 65 (25-98)
First breast cancer diagnosis at age <40 y
≤5 180 485 11 22.7 (12.6-41.0) 9 (5-17)
>5-10 163 542 9 16.6 (8.6-31.9) 17 (11-25)
>10-15 104 314 5 15.9 (6.6-38.2) 23 (16-32)
>15-20 58 149 4 26.9 (10.1-71.5) 31 (22-43)
>20-43 29 127 2 15.8 (3.9-63.0) 68 (29-98)
First breast cancer diagnosis at age ≥40-50 y
≤5 206 550 7 12.7 (6.1-26.7) 6 (3-14)
>5-10 181 554 9 16.3 (8.5-31.2) 14 (8-22)
>10-15 107 322 5 15.5 (6.5-37.3) 20 (13-29)
>15-20 52 143 1 7.0 (1.0-49.6) 23 (15-35)
>20-37 29 123 1 8.1 (1.2-57.7) 28 (17-44)
First breast cancer diagnosis at age ≥50 y
≤5 179 433 9 20.8 (10.8-40.0) 9 (5-17)
>5-10 132 447 8 17.9 (9.0-35.8) 17 (11-27)
>10-15 74 244 1 4.1 (0.6-29.1) 20 (13-30)
>15-20 28 63 0 0.0 20 (1330)
>20-30 10 40 0 0.0 20 (1330)
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carriers using data from a prospective cohort. Because the
study mainly included unaffected women identified by
mutation screening based on cancer family history, early age
at onset of a family member, or both, the overall estimates
are relevant to mutation carriers identified through clinical
testing. However, the wide range of family histories repre-
sented allowed an examination of the relationship between
family history and cancer risk. The results indicate that fam-
ily history is a strong risk factor for mutation carriers and that
cancer risks vary by mutation location, suggesting that indi-
vidualized counseling should incorporate both family history
profiles and mutation location.
The cumulative risk of developingbreast cancer by age80
yearswas72%forBRCA1mutationcarriers and69%forBRCA2
mutation carriers, respectively. For ovarian cancer, the cumu-
lative risks by age 80 years were 44% for BRCA1 carriers and
17%forBRCA2 carriers. Breast cancer incidence for carriers in-
creased rapidlywith age in early adulthood thenplateaued to
remain relatively constant throughout the remaining life-
time. The age at which this plateau was reached was 31 to 40
years for BRCA1 carriers and 5 to 10 years later for BRCA2 car-
riers. The incidence during the plateau was similar for both
groups ofmutation carriers. This is consistentwith themodel
for genetic riskof breast cancer basedon twindata,20 inwhich
Table 4. Hazard Ratio Estimates for Breast and Ovarian Cancer AssociatedWith Family History of Breast or Ovarian Cancer
in First- and Second-Degree Relatives and Corresponding Cumulative Risk Estimates
Family History Category
No. of
Women
No. of
Person-Years
No. of
Events
Hazard Ratio
(95% CI) P Value
Cumulative Risk by Age, % (95% CI)
40 y 50 y 60 y 70 y
Breast cancer risk
for BRCA1 mutation carriers
No breast cancers 600 3283 54 1 [Reference] 16 (10-23) 35 (27-44) 43 (34-53) 53 (39-69)
1 breast cancer 719 4176 91 1.51 (1.08-2.11) .02 27 (21-35) 47 (40-55) 56 (48-64) 68 (59-77)
≥2 breast cancers 737 3864 108 1.99 (1.41-2.82) <.001 31 (23-40) 50 (42-58) 67 (60-75) 73 (65-80)
Family history unknown 205 906 13 1.06 (0.54-2.08) .86
Cancer type unknown
in family
15 128 3 2.57 (1.16-5.71) .02
≥1 breast cancers 1456 8040 199 1.67 (1.23-2.26) .001 28 (23-34) 48 (43-54) 62 (57-68) 71 (66-80)
Per affected relative
with breast cancer
1.15 (1.07-1.24) <.001
Breast cancer risk
for BRCA2 mutation carriers
No breast cancers 302 1499 17 1 [Reference] 5 (1-18) 26 (16-40) 39 (25-56) 39 (25-56)
1 breast cancer 495 2675 49 1.53 (0.86-2.70) .15 14 (8-24) 30 (21-41) 55 (44-67) 62 (51-74)
≥2 breast cancers 634 3112 78 1.91 (1.08-3.37) .02 14 (8-24) 40 (32-50) 57 (48-66) 65 (56-74)
Family history unknown 166 575 13 1.82 (0.80-4.14) .15
Cancer type unknown
in family
13 53 0
≥1 breast cancers 1129 5787 127 1.69 (0.99-2.88) .05 14 (9-21) 36 (30-43) 56 (49-63) 64 (57-71)
Per affected relative
with breast cancer
1.15 (1.02-1.30) .02
Ovarian cancer risk
for BRCA1 mutation carriers
No ovarian cancers 1706 8774 46 1 [Reference] 2 (1-4) 7 (4-11) 15 (10-21) 41 (30-53)
1 ovarian cancer 689 3286 21 1.24 (0.75-2.03) .40 1 (0-6) 11 (6-20) 27 (16-43) 45 (30-64)
≥2 Ovarian cancers 228 1117 12 1.77 (0.90-3.46) .10 5 (1-18) 15 (7-31) 40 (23-62) 45 (27-67)
Family history unknown 230 1000 4 1.08 (0.36-3.23) .90
Cancer type unknown
in family
52 368 2 1.21 (0.29-5.07) .79
≥1 ovarian cancers 917 4403 33 1.37 (0.89-2.11) .16 2 (1-6) 12 (8-20) 31 (22-43) 44 (32-58)
Per affected relative
with ovarian cancer
1.20 (0.94-1.55) .15
Ovarian cancer risk
for BRCA2 mutation carriers
No ovarian cancers 1558 7845 18 1 [Reference] 0 0 6 (3-12) 16 (10-25)
1 ovarian cancera 331 1463 4 1.26 (0.43-3.69) .67
≥2 Ovarian cancers 55 215 1
Family history unknown 169 558 1 0.83 (0.10-6.70) .87
Cancer type unknown
in family
48 257 0
≥1 ovarian cancers 386 1678 5 1.09 (0.37-3.25) .87 1 (0-10) 1 (1-10) 8 (2-26) 15 (5-39)
Per affected relative with ovarian cancer 0.94 (0.39-2.26) .90
a Numbers too small to obtain estimates.
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Table 5. Hazard Ratio Estimates for Breast and Ovarian Cancer AssociatedWithMutation Location and Corresponding Cumulative Risk Estimates
Mutation Location Category
No. of
Women
No. of
Person-Years
No. of
Events
Hazard Ratio
(95% CI) P Value
Cumulative Risk by Age, % (95% CI)
40 y 50 y 60 y 70 y
Breast cancer risk
for BRCA1 mutation carriers
5′ to c.2281 926 5014.1 116 1.43 (1.05-1.94) .02 26 (20-33) 46 (39-53) 60 (53-67) 68 (60-77)
c.2282 to c.4071 671 3631.2 62 1 [Reference] 15 (9-22) 34 (27-43) 48 (39-58) 56 (46-67)
c.4072 to 3′ 672 3684.8 91 1.51 (1.10-2.08) .01 31 (24-39) 48 (41-57) 58 (50-67) 71 (62-80)
Missinga 7 26.0 0
5′ to c.2281
and c.4072 to 3′
1598 8698.9 207 1.46 (1.11-1.93) .007 28 (23-33) 47 (42-52) 59 (54-65) 70 (64-76)
Ashkenazi Jewish
mutations
Non-Ashkenazi
mutations
in 5′ to c.2281
and c.4072 to 3′
1226 6506.0 150 1 [Reference] 27 (21-33) 46 (40-52) 57 (51-64) 69 (62-77)
c.68_69delAG 185 1163.0 33 1.37 (0.91-2.07) .14 24 (14-39) 44 (32-60) 73 (57-87) 84 (68-94)
c.5266dupC 187 1029.9 24 1.22 (0.76-1.94) .41 39 (26-56) 52 (38-68) 60 (45-75) 60 (45-75)
Ovarian cancer risk
for BRCA1 mutation carriers
5′ to c.2281 1176 5900.6 33 0.71 (0.42-1.20) .20 2 (1-5) 7 (4-13) 19 (13-28) 36 (25-50)
c.2282 to c.4071 802 3859.2 30 1 [Reference] 1 (0-5) 13 (8-22) 27 (18-39) 51 (36-67)
3′ to c.4072 921 4769.0 22 0.66 (0.39-1.13) .13 2 (0-5) 6 (3-12) 16 (9-28) 39 (26-56)
Missinga 6 16.0 0
5′ to c.2281
and c.4072 to 3′
2097 10669.6 55 0.69 (0.43-1.10) .12 2 (1-4) 7 (4-10) 18 (13-24) 37 (28-48)
Ashkenazi Jewish
mutations
Non-Ashkenazi
mutations
in 5′ to c.2281
and c.4072 to 3′
1552 7714.6 40 1 [Reference] 2 (1-4) 7 (4-11) 17 (11-25) 40 (29-54)
c.68_69+delAG 281 1614.0 11 1.03 (0.50-2.14) .93 3 (1-12) 8 (3-22) 26 (14-45) 35 (20-56)
c.5266dupC 264 1341.0 4 0.57 (0.22-1.48) .25 3 (0-17) 10 (2-40) 34 (13-73)
Breast cancer risk
for BRCA2 mutation carriers
Narrow definition
of the ovarian cancer
cluster region
5′ to c.3846 492 2341.3 47 1.63 (1.07-2.49) .02 14 (8-25) 41 (31-53) 52 (41-64) 69 (55-81)
c.3847 to c.6275 538 2994.3 45 1 [Reference] 6 (3-15) 18 (12-28) 42 (32-53) 51 (39-63)
c.6276 to 3′ 571 2601.5 63 1.77 (1.16-2.70) .008 20 (12-32) 44 (34-54) 61 (51-71) 67 (57-76)
Missinga 9 26.0 2
5′ to c.3846
and 3′ to c.6276
1063 4942.8 110 1.70 (1.18-2.46) .005 17 (11-24) 42 (35-50) 57 (50-65) 66 (58-74)
Wide definition
of the ovarian cancer
cluster region
5′ to c.2830 406 1941.3 42 1.95 (1.28-2.99) .002 16 (9-29) 45 (34-57) 55 (43-68) 69 (56-82)
c.2831 to c.6401 634 3414.3 50 1 [Reference] 5 (2-12) 18 (12-27) 40 (31-51) 51 (40-63)
3′ to c.6402 561 2531.5 63 1.91 (1.28-2.85) .001 20 (12-32) 44 (35-55) 62 (52-72) 68 (58-77)
Missinga 9 26.0 2
5′ to c.2830
and c.6402 to 3′
967 4472.8 105 1.93 (1.36-2.74) <.001 18 (12-26) 44 (37-52) 59 (52-67) 68 (60-75)
Ashkenazi Jewish
mutations
Non-Ashkenazi
mutations
in c.2831 to c.6401
543 2828.3 43 1 [Reference] 6 (3-15) 22 (14-31) 42 (32-53) 53 (41-67)
c.5946delT 91 586.0 7 0.73 (0.35-1.54) .41 32 (14-62) 41 (20-70)
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the age-specific incidence for genetically susceptible women
increases to a high constant level by a predetermined age that
varies among families.
The estimated breast and ovarian cancer risks were con-
sistent with findings from retrospective family-based
studies.2,3,6,10 The breast cancer SIRs decreasedwith increas-
ing age for both BRCA1 and BRCA2 carriers, but the estimates
were higher than those previously reported for younger age
groups.2,21 From this prospective study, the estimated cumu-
lative risks of ovarian cancer were low up to age 40 years for
BRCA1 mutation carriers and up to age 50 years for BRCA2
mutation carriers.
This studywas limited in the extent to which differences
by birth cohort could be assessed because birth cohort was
strongly associatedwith age. For age intervalswith sufficient
observations, therewasnoevidenceof riskdifferencesbybirth
cohort (eFigure 5 in the Supplement).
In line with retrospective studies of contralateral breast
cancer risks,22,23 thepresentprospectiveanalysisofBRCA1and
BRCA2carriers combineddemonstratedahigher riskwhenthe
first breast cancer was diagnosed before age 40 years vs after
age 50 years (P = .03).
The contralateral breast cancer analysis also included
women diagnosed as having breast cancer prior to study re-
cruitment. Themedian interval between first breast cancerdi-
agnosis and study recruitment was 4 years, and this did not
vary by age at first breast cancer diagnosis or by gene. The in-
clusion of survivors could potentially bias the estimation of
contralateral breast cancer risks if such risks were related to
theoutcomeof the first cancer;however, there isnostrongevi-
dence of such a relationship in the general population. Fur-
thermore, the results were similar after excluding women
whose first breast cancerdiagnosis occurredmore than5years
prior to study recruitment, suggesting that any bias is likely
to be small. Contralateral breast cancer riskshavebeen shown
to be reduced by adjuvant treatment of the first cancer.24,25
BRCA2 carriers are more likely to develop estrogen receptor–
positive cancers, so their lower contralateral breast cancer risk
estimates may in part be due to greater use of endocrine
therapy.Hormoneandchemotherapeutic treatmentswerenot
considered, so the present estimates represent risks aver-
aged over different treatments.
Therewas increasingbreast cancer risk forbothBRCA1and
BRCA2 carriers with increasing number of relatives who had
been diagnosedwith breast cancer. Similar patterns were ob-
served for the risk of ovarian cancer but the number of events
for women with family history of ovarian cancer was small.
Theoverall breast cancer riskestimateswere somewhathigher
than thoseestimatedbykin cohort analyses, inwhich the risks
are derived from cohorts of relatives of carriers identified
among unselected cases.3,21 The present cohort of mutation
carrierswasprimarily identified throughclinical genetics cen-
ters and included women who, on average, are likely to have
stronger familyhistoryof cancer comparedwithmutationcar-
riers identified through population-based sampling of
cases. Therefore, a likely explanation for the higher esti-
mated risks in the present study is that cancer risks formuta-
tion carriers are modified by genetic and nongenetic risk fac-
torswhichaggregate in families, in linewithevidencethatother
genetic factorsmodifycancer risks formutationcarriers.18,26-29
Table 5. Hazard Ratio Estimates for Breast and Ovarian Cancer AssociatedWithMutation Location and Corresponding Cumulative Risk Estimates
(continued)
Mutation Location Category
No. of
Women
No. of
Person-Years
No. of
Events
Hazard Ratio
(95% CI) P Value
Cumulative Risk by Age, % (95% CI)
40 y 50 y 60 y 70 y
Ovarian cancer risk
for BRCA2 mutation carriers
Narrow definition
of the ovarian cancer
cluster region
5′ to c.3846 655 3002.5 6 0.83 (0.27-2.52) .75 5 (1-19) 18 (8-36)
c.3847 to c.6275 733 3793.0 11 1 [Reference] 1 (0-5) 1 (0-5) 9 (4-18) 14 (8-26)
3′ to c.6276 761 3508.0 7 0.67 (0.22-2.00) .47 6 (2-15) 17 (7-38)
Missinga 12 34.0 0
5′ to c.3846 and c.6276 to 3′ 1416 6510.5 13 0.75 (0.29-1.93) .55 5 (2-11) 17 (10-29)
Wide definition
of the ovarian cancer
cluster region
5′ to c.2830 539 2459.5 6 1.07 (0.36-3.17) .91 6 (2-23) 21 (10-41)
c.2831 to c.6401 867 4426.0 11 1 [Reference] 1 (0-5) 1 (0-5) 8 (4-16) 13 (7-23)
c.6402 to 3′ 743 3418.0 7 0.78 (0.27-2.30) .65 6 (2-16) 17 (7-38)
Missinga 12 34.0 0
5′ to c.2830 and c.6402 to 3′ 1282 5877.5 13 0.91 (0.36-2.28) .84 6 (3-12) 18 (10-32)
Ashkenazi Jewish mutations
Non-Ashkenazi mutations
in c.2831 to c.6401
744 3796.0 11 1 [Reference] 1 (0-6) 1 (0-6) 9 (4-19) 16 (8-28)
c.5946delT 123 630.0 0
a Numbers too small to obtain estimates.
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These results confirm that family history shouldbe taken into
account in determining cancer risks for carriers, as modeled
explicitly in BOADICEA.3
This prospective analysis validates retrospective analy-
ses demonstrating that cancer risk varies by mutation loca-
tion within the BRCA1 or BRCA2 gene.16-18 Consistent with
those findings,mutations that lie inexon 11of either genewere
associatedwith a lower breast cancer risk andpossibly higher
ovarian cancer risk. The number of women in this prospec-
tive cohort was too small to estimate risks for additional, re-
cently identified breast or ovarian cancer cluster regions.18
This study has several limitations. Data on tumor pheno-
typesof cancerswerenot available. Therefore, the results rep-
resentaverageestimatesoverallphenotypesofbreastandovar-
ian cancer.Although therewasvariation in the cancer risks for
mutation carriers by cancer family history, the study sample
was not identified through population screening of unaf-
fectedwomen.Therefore, theoverall estimatesmaynot bedi-
rectly applicable to suchwomen. The present results suggest
that cancer risks for women with no family history are likely
to be lower than those estimated here. The cancer risk esti-
matesmay be subject to some selection bias if the decision to
participate in the study or opt for testing was related to fac-
tors that are associated with disease risk. It was not possible
to contrast the unaffected study participants to all other un-
affected familymemberswhohadnegative test results orwho
didnotopt for a genetic test or for studyparticipation, as those
data could not be collected. However, the analysis by family
history addresses possible selection biaswith respect to fam-
ily history of cancer and the family history–specific estimates
are expected to be unbiased. The number of events in some
of the subgroups considered was small and therefore the es-
timates have wide confidence intervals. Family size was not
taken into consideration because data on unaffected family
members were not collected systematically. In addition, risk
estimates are limited by the lack of information about the use
of hormone therapies to prevent either first primary or con-
tralateral breast cancers.
Conclusions
These findings provide information on cancer risk for BRCA1
andBRCA2mutation carriersusingprospectivedata anddem-
onstrate the potential importance of family history and mu-
tation location in risk assessment.
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